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Abstract. Diagnostic accuracy of needle-based optical coherence tomography (OCT) for prostate cancer detec-
tion by visual and quantitative analysis is defined. 106 three-dimensional (3-D)-OCT data sets were acquired in
20 prostates after radical prostatectomy and precisely matched with pathology. OCT images were grouped per
histological category. Two reviewers performed blind assessments of the OCT images. Sensitivity and specificity
for malignancy detection were calculated. Quantitative analyses by automated optical attenuation coefficient
calculation were performed. OCT can reliably differentiate between fat, cystic, and regular atrophy and benign
glands. The overall sensitivity and specificity for malignancy detection was 79% and 88% for reviewer 1 and
88% and 81% for reviewer 2. Quantitative analysis for differentiation between stroma and malignancy showed
a significant difference (4.6 mm−1 versus 5.0 mm−1 Mann–Whitney U-test p < 0.0001). A Kruskal–Wallis test
showed a significant difference in median attenuation coefficient between stroma, inflammation, Gleason 3, and
Gleason 4 (4.6, 4.1, 5.9, and 5.0 mm−1, respectively). However, attenuation coefficient varied per patient and
a related-samples Wilcoxon signed-rank test showed no significant difference per patient (p ¼ 0.17). This study
confirmed the one to one correlation of histopathology and OCT. Precise matching showed that most histological
tissues categories in the prostate could be distinguished by their unique pattern in OCT images. In addition,
the optical attenuation coefficient can play a role in the differentiation between stroma and malignancy; however,
a per patient analysis of the optical attenuation coefficient did not show a significant difference. © The Authors.
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1 Introduction
Prostate cancer consisted 26% of the new cancer diagnoses in
2015, and it was the second most common cause of cancer-
related death in the USA.1 Prostate specific antigen (PSA)
screening led to an increase in the diagnosis of low- and inter-
mediate risk prostate cancer.2 Focal therapy is emerging as an
attractive treatment option for these patients since it only treats
the cancerous part of the prostate while leaving the remaining
part unharmed. Focal therapy has significantly fewer side effects
when compared to radical treatment.3–9 However, accurate
imaging on a microscopic level is crucial for case selection and
the application of focal therapy.
Imaging technologies that are currently investigated for pros-
tate cancer include multiparametric MRI and transrectal ultra-
sound (TRUS).10 These technologies provide information on a
macroscopic level with voxel sizes of ∼1 mm3 on MRI and pixel
sizes of ∼0.2 mm × 0.2 mm on TRUS. Standard histopathology
provides diagnostic information on prostate cancer on a micro-
scopic level. This process, however, is time consuming, moder-
ately reproducible between observers, and produces artifacts
on subsequent radiological images.11,12 An imaging modality
that provides reproducible instant information on a microscopic
level and that can be used intraoperatively and in the outpatient
department would make the process of diagnosis, treatment,
and monitoring faster (automated image processing) and more
accurate (less open for interpretation error).
Optical coherence tomography (OCT) is a high-resolution
imaging method in which contrast is based on differences
between light scattering of tissue structures.13 Although the im-
aging depth is limited to ∼2 mm, OCT has an important advan-
tage over standard histopathology, because OCT can, either
non- or minimally invasively, be applied in vivo, using scan
heads or probes in conjunction with balloons, catheters, or
needles. Recent developments in needle-based OCT enable
minimally invasive puncturing of tissue and therefore in-tissue
imaging.14,15 Furthermore, the OCT signal can be quantitatively
analyzed, thereby providing tissue-specific parameters such as
the optical attenuation coefficient.14,16 The optical attenuation
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coefficient can function as a measure for tissue density. In pre-
vious studies, one to one matching of the OCT images with
histology remained challenging,14,16 whereas precise histopa-
thology correlation is essential to draw well-founded conclu-
sions from the measured OCT data and to understand which
tissue types in the prostate can be distinguished by OCT.
Therefore, a customized prostate measurement and slicing
device was developed which facilitates the necessary one to
one correlation of OCT images of fresh prostate tissue with his-
tology. It has been demonstrated that OCT is able to characterize
tissue structures as seen on histopathology.17–19 In addition, the
tissue density is expected to translate into a different attenuation
coefficient when compared with benign tissue. The objectives of
the present study are to identify unique structural characteristics
in needle-based OCT images, which by pathology are proven
benign or malignant prostatic tissues, based on visual parame-
ters and/or quantitative analyses by means of the optical attenu-
ation coefficients. We hypothesize that the obtained structural
characteristics and quantitative parameters can be translated
into a diagnostic accuracy that approaches biopsy levels. The
study is performed according to the IDEAL guidelines for the
validation of medical devices20 and according to the STARD
criteria for diagnostic studies.21
2 Methods
A prospective observational ex vivo study was performed in
20 prostates immediately after radical prostatectomy. The hos-
pital’s ethical board waived the need for evaluation.
2.1 Participants
Patients at least 18 years of age, diagnosed with prostate cancer,
and scheduled for radical prostatectomy were eligible for inclu-
sion in this study. Potentially eligible patients were identified
at the outpatient clinic of the urology department at the VU
University Medical Center in Amsterdam between August and
November 2014. Inclusion was on a consecutive basis.
2.1.1 Test methods
OCT measurements were recorded using a commercially avail-
able C7-XRtm Imaging System interfaced to a C7 dragonflytm
imaging probe (St. Jude Medical, St. Paul, Minnesota) (Fig. 1).
The system uses a wavelength of 1300 nm with a bandwidth of
55 nm, with a scanrate of 100 frames∕s (500 A-lines/frame).22,23
The imaging probe was inserted into a transparent intravascular
(IV)-needle catheter (Terumo Surflo© 18 G × 2½) allowing
tissue puncturing. A detailed description of the device, its
adaption for prostate imaging, and the measurement protocol
were provided in a previous paper.14 Briefly, the rotating
fiber-optic probe with an outer diameter of 2.7 Fr (0.9 mm)
produces cross-sectional images with an axial resolution of
10 to 15 μm and lateral resolution of 20 to 40 μm.24 A 360-deg
probe rotation provides 504 A-scans of ∼5 mm. The 504
A-scans were converted into one cross-sectional image or
B-scan. In the cylindrical configuration, the B-scan is thus
presented with a diameter of 10 mm. The automatic pullback
system scans over a trajectory of 54 mm in ∼5.4 s, producing
a 540-frame/B-scan dataset, resulting in a cylindrical scan of
the prostate tissue of 54 mm × 10 mm, with an imaging depth
of 2 mm limited by scattering.14
Ex vivo OCT measurements were performed in fresh tissue at
the pathology department directly following radical resection.
Four (in a small prostate) or six (in a large prostate) intravascular
(IV)-catheters were placed in the prostate using the customized
tool as described in previous work.25 After removal of the inser-
tion needle, the C7 dragonflytm OCT probe was inserted into
the in-situ transparent IV catheter and OCT measurements of
the prostate tissue were acquired.
2.1.2 Histopathological evaluation
The prostate was sliced after 48 h formaldehyde fixation. For
slicing, the knife was guided through the OCT imaging trajec-
tory (Fig. 2).25 Whole mount histopathological slides were pro-
duced and stained with hematoxylin and eosin according to the
standard VUMC pathology protocol. The histological diagnosis
was made by an expert uropathologist who was informed
about biopsy and clinically relevant findings but blinded for
the OCT results. Afterward, all whole mount slides were digi-
tized. The pathologist performed the marking and annotation of
histological structures in the digitized whole mount slides using
annotation software designed by our department. Nine histopa-
thological tissue categories were annotated: cystic atrophy,
regular atrophy, benign glands, stroma, inflammation, fat and
malignancy Gleason pattern 3, Gleason pattern 4, and Gleason
pattern 5.
2.1.3 Data analysis
Measurement of the histopathological OCT trajectory length
was performed using the pathology annotation software after
digital scale calibration to correct for prostate shrinkage after
fixation. A starting point was defined at the border of the pros-
tate. Total trajectory length and all distances from the beginning
of the trajectory to marked histological structures were mea-
sured. This procedure was performed for the histological struc-
tures on both sides of the trajectory [ventral (painted red and
yellow) and dorsal (painted blue and green)]. The OCT scan
Fig. 1 The St. Jude OCT system. (a) C7-XRtm OCT console. (b) The
C7 dragonfly OCT imaging probe connected to the OCT driver con-
taining the optical fiber and focusing optics and electronic compo-
nents for measurements. (c) Schematic detail of the OCT probe: the
light is deflected perpendicular to the probe’s axis into the tissue
while the probe rotates and is pulled back, resulting in a cylindrically
scanned OCT volume of the tissue surrounding the probe.
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creates a 360-deg view of the tissue. Histopathology was two-
dimensional (2-D) and thus contained only information in one
plane. Rotational matching was ensured by overlapping identi-
cal structures seen in histopathology and OCT, as is indicated by
the arrows in Fig. 3. The urethra and outer shape of the prostate
provided a rough estimation of orientation. Cysts were used for
final precise orientation.
The B-scan locations were matched to the distances mea-
sured in the histological slides. Based on this information,
a virtual overlay of the OCT scan over the histology was made.
In this way, the histological classification of every single B-scan
was deduced.
2.1.4 Qualitative data analysis
For each of the nine histological categories, locations were
selected where opposing sites (ventral and dorsal to the imaging
trajectory) were classified in the same category; we refer to these
regions as the regions of interest (ROIs). On these locations, we
assume that all tissue surrounding the catheter channel has the
same histological characteristics. The corresponding OCT B-
scans were saved to a database. Subsequently, 110 B-scans
across the histological categories were selected by RK, random-
ized, and offered to two reviewers (BM and AS) blinded for the
biopsy histology assessment and further clinical information.
Prior to analysis, the two reviewers received a short training
based on example images and a short qualitative description
of the OCT images. Both reviewers independently assigned
the B-scans to one of the nine histological categories for com-
parison to the histological classification.
2.1.5 Quantitative data analysis
Quantification of the optical attenuation coefficient was per-
formed using custom-written code (Matlab 7.11.0 R2010b,
The Mathworks Inc., Natick, Massachusetts). The optical
attenuation coefficients from the ROIs were obtained by
processing the data according to steps shown in Fig. 4. The
region of interest (ROI) is divided into fit regions (FR) with
the following dimensions: (31 × 6 A-lines). Each separate
A-line in an FR was laterally averaged, and attenuation coeffi-
cient (μOCT) was fitted according to the method in Appendix
yielding 1 μOCT per fit region, which correspond to a specific
location in the histopathology. These values were used for
analysis.
The process is described in detail in Appendix and shown in
Fig. 5. We used our experience from previous work to design
the program.14,16,26
In order to improve the data quality, a margin of error was
included for the OCT–histopathology correlation process. Five
B-scans, covering 0.5 mm in scan length, at the beginning and
end of each ROI were deleted. The remaining ROIs had to
Fig. 3 Correlation of histology and OCT. (a) Digitized H&E-stained
whole mount slide of the prostate. The two (horizontal) trajectories
from the OCT measurements are clearly visible. The pathologist
annotates the tissue types in different colors. The black arrow indi-
cates an atrophic cyst. (b) An OCT B-scan at the level of the atrophic
cyst from (a). The blue arrow shows the same atrophic cyst. The blue-
yellow line corresponds with the longitudinal cross section of the
cylindrical dataset depicted in (c). (c) A longitudinal cross section
of the OCT scan, also used for final rotational correlation with histol-
ogy. The blue arrow indicates the atrophic cyst, seen in (a) and (b).
(d) 3-D visualization of OCT images matched one-to-one with
histopathology.
Fig. 2 Customized prostate measurement and slicing tool. (a) First,
the prostate is fixed between two grids, ensuring parallel IV catheter
insertion for measurements. Four stabilizing needles in the middle
ensure that the prostate does not move during slicing (red arrow
in b). (b) OCT measurements are performed. Afterward, the prostate
is fixated for 48 h in formalin. (c) The prostate is placed in the
slicing device, with knife guiders surrounding the knife, ensuring that
the prostate is sliced perfectly through the OCT imaging trajectory.
(d and e) The procedure is extensively described in earlier work.25
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contain at least six B-scans for final inclusion. The attenuation
coefficients of these regions were stored in a database based on
the histologic classification. The determined values for stroma,
inflammation, and all malignancy categories were grouped per
patient. In case of missing data of whole mount slides or OCT
scans, the specific OCT scan/histology combination was
excluded from the analysis.
2.1.6 Statistics
The results of the visually reviewed OCT B-scan were compared
to the whole mount histopathology slides. In addition, answers
were grouped based on similar histological classification.
Finally, all scores were grouped for benign and malignant his-
tology. Sensitivity, specificity, false negative, and false positive
Fig. 4 Automated quantitative analysis. The process is described in detail in Appendix.
Fig. 5 (a) First, tissue types were assigned by the pathologist, (b) Regions were selected with the same
histopathology on both sides of the imaging trajectory, 5 B-scans on both sides of the ROI were taken as a
safety margin and not included in the analysis. The B-scans in this region (dotted yellow line and example in
c) were further analyzed as described in Appendix (d). The fit starts 20 pixels after reaching tissue surface,
the fitlength is 226 pixels. An average of the final 100 pixels was used as a measurement of the noise.
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calculations were performed manually using a 2 × 2 table. The
interobserver agreement expressed in kappa was calculated for
every category. Kappa (k) <0 was defined as “poor agreement,”
0 to 0.20 “slight agreement,” 0.21 to 0.4 “fair agreement,”
0.41 to 0.60 “moderate agreement,” 0.61 to 0.8 “substantial
agreement,” and above 0.81 “almost perfect agreement.”
Optical attenuation coefficients of malignancy Gleason
patterns 3, 4, and 5 were grouped. With a Kolmogorov–Smirnov
test, data were tested for a normal distribution. A Mann–
Whitney U test was performed for comparison of the attenuation
coefficient of stroma and malignancy, using MedCalc v 15.8.
A Kruskal Wallis test was performed to compare attenuation
coefficients of stroma, inflammation, Gleason 3, and Gleason
4 individually. A p-value of ≤0.05 stated significance. In addi-
tion, receiver operating characteristic (ROC) curve analyses
were performed. The area under the curve (AUC) was calculated
to determine test accuracy.
3 Results
3.1 Patient Characteristics
Patient characteristics are described in Table 1: 20 consecutive
patients were included. On these 20 prostates, 106 three-dimen-
sional (3-D)-OCT measurements were performed. The mean age
was 65 years with a mean PSA of 11.5 ng∕ml at the time of
surgery. All patients except one underwent prostate biopsies
with Gleason scores ranging from 3þ 3 to 4þ 4. One patient
was included based on benign prostate hyperplasia transurethral
resection results. Histologic specimen examination provided
Gleason scores ranging from 3þ 4 to 4þ 5 and one benign
specimen. Seminal vesicle invasion, extracapsular invasion,
pelvic lymph node involvement, and positive resection margins
were present in two, six, one, and five patients, respectively.
3.2 OCT and Histology Correlation
A total number of 52 whole mount histopathological slides were
available. The OCT trajectories were visible in 50 slides.
Malignancy was visible in 19 histology slides in 13 prostates.
Twenty-one slides were damaged during production, resulting in
areas with data loss. Matching of OCT scans with histology was
achieved with high precision in 36 slides. The urethra and outer
boundaries of the prostate contributed to the first rotational
orientation. Mainly cysts but also other landmarks such as the
urethra provided data for precise rotational orientation as can be
seen in Fig. 3. Rotational inaccuracy was estimated at 10 deg.
3.3 Qualitative Description of B-Scans
The earlier selected representative OCT B-scans that were
grouped per histopathological tissue type were reviewed for
identification of unique marks on OCT. Figure 6 shows a rep-
resentative B-scan per category. Review of the B-scans showed
that part of the histopathology was well identifiable by OCT
based on unique characteristics. Cystic atrophy [Fig. 6(1)]
was visually identified by cavities (>0.5 mm), divided by
septae. The content of the cavities appears opaque due to back-
scattered light. Regular atrophy [Fig. 6(2)] has smaller (0.1 to
0.3 mm), dark, more grouped cavities than those found in cystic
atrophy. Benign glands [Fig. 6(3)] have even smaller, mostly
grouped cavities (≤0.1 mm). The cavities could be dark or
opaque. Fat [Fig. 6(4)] had a honeycomb structure, consisting
of a unique pattern of bright stripes, alternated by dark dots.
The remaining histopathological classifications were more
difficult to distinguish by OCT. Malignancy Gleason patterns
3 and 4 [Figs. 6(5) and 6(6)] present as homogeneous tissue
structures. High signal surrounding the probe and low signal
in depth represented a low signal penetration (<1 mm), probably
due to a high cell density. Stroma [Fig. 6(7)], similarly to malig-
nant tissue, appeared homogeneous but with an increased signal
depth (≥1 mm). Parallel ellipsoidal-shaped lines on both sides
of the probe were unique for stroma and probably caused by
fibrotic tissue, yet this was not seen in all stromal B-scans.
Inflammation [Fig. 6(8)] had a homogeneous pattern with
high cell density and signal penetration of ∼1 mm, with vague
outer boundaries.
3.4 Qualitative Blind Assessment of B-Scans
Blind assessment of OCT B-scans was done by two reviewers
(see Table 2). The percentages represent the number of B-scans
correctly scored by the reviewer. Grouping scores for categories
with similar histology and intended treatment improved the
results. Combining benign glands, cystic atrophy, and regular
atrophy resulted in scores of 100% and 88.9%. The combination
Table 1 Patient characteristics.
Patients n ¼ 20
Age at operation (years) mean: 64.5
(range: 55 to 76)
PSA at operation (ng/ml) mean: 11.5
(range: 2.9 to 36)a
Biopsies (Gleason) 3 + 3 n ¼ 5
3 + 4 n ¼ 11
4 + 3 n ¼ 2
4 + 4 n ¼ 1
Total number of cores mean: 9.6
(range: 6 to 15)
Number of cores positive mean: 4
(range: 1 to 7)b
Specimen (Gleason) 0 + 0 n ¼ 1
3 + 4 n ¼ 7
4 + 3 n ¼ 11
4 + 5 n ¼ 1
Seminal vesicle invasion n ¼ 2
Extracapsular invasion n ¼ 6
Pelvic lymph node dissection n ¼ 7
Lymph node involvement n ¼ 1
Resection margins positive n ¼ 5
a2.9 under Combodart.
bOne patient underwent a radical prostatectomy based on a histopa-
thological Gleason score 4 + 4 after transurethral resection of the
prostate.
Journal of Biomedical Optics 086001-5 August 2018 • Vol. 23(8)
Muller et al.: Needle-based optical coherence tomography for the detection of prostate cancer: a visual and quantitative. . .
Downloaded From: https://www.spiedigitallibrary.org/journals/Journal-of-Biomedical-Optics on 15 Jul 2019
Terms of Use: https://www.spiedigitallibrary.org/terms-of-use
of stroma and inflammation resulted in scores of 56% and 59%.
Malignancy Gleason patterns 3, 4, and 5 resulted in correct
scores of 79% and 88%. In particular, stroma and inflammation
were most often misidentified, totaling n ¼ 17 and n ¼ 17 out
of 41 for reviewers 1 and 2, respectively. Grouping malignant
and benign scores gave an overall sensitivity and specificity
for malignancy detection of 79% and 88% for reviewer 1,
and 88% and 81% for reviewer 2. Negative predictive values
were high (94% and 96% for reviewers 1 and 2, respectively).
Positive predictive values were relatively low (66% and 57% for
reviewers 1 and 2, respectively).
The interobserver agreement on OCT images was calculated
and resulted in moderate agreement between observers
(weighted kappa of 0.50 for overall test values).
When test results were combined into similar groups with
similar histology and intended treatment, benign cystic struc-
tures (benign/cystic and regular glands), benign stromal struc-
tures (stroma/inflammation), and malignant structures (Gleason
pattern 3/4/5), there was substantial agreement between observ-
ers (kappa of 0.64). When the results were grouped in two
groups: benign structures (stroma and inflammation) and malig-
nant structures (Gleason pattern 3/4/5), there was moderate
agreement between observers (kappa of 0.57).
3.5 Quantitative Analysis: Attenuation Coefficient
Automated attenuation coefficient calculations were performed
for additional differentiation between stroma and malignancy.
Twelve patients were included; eight patients could not be
included in the analysis, as the tumor or inflammation was
not scanned by OCT.
We noticed that the attenuation coefficient (malignant and
benign) differed per patient.
Fig. 6 Histological tissue characteristics seen in OCT. The inner part of the OCT probe and the IV cath-
eter in the middle are made black.
Table 2 Results of visual OCT B-scan scoring.
Reviewer 1 Reviewer 2
Scores Exact Percentage Exact Percentage
Benign glands 15/16 94% 11/16 69%
Cystic atrophy 8/9 89% 7/9 78%
Regular atrophy 8/11 72% 4/11 36%
Stroma 16/31 52% 13/31 42%
Gleason pattern 3 2/5 40% 3/5 60%
Gleason pattern 4 9/19 47% 6/19 32%
Inflammation 1/10 10% 4/10 40%
Fat 9/9 100% 9/9 100%
Grouped scores
Benign, cystic, regular 36/36 100% 32/36 89%
Stroma, inflammation 23/41 56% 24/41 59%
Malignancy 3,4,5 19/24 79% 21/24 88%
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The attenuation coefficient was higher for malignancy than
for stroma (5.0 mm−1 versus 4.6 mm−1). This yields for most
patients except four (Table 3, Fig. 7). Data were tested for a nor-
mal distribution with a Kolmogorov–Smirnov test, and normal-
ity was rejected in both benign and malignant data (p < 0.0001).
A Mann–Whitney U test showed a significant difference in
attenuation coefficient (p < 0.0001). Additional analyses with
an ROC curve as accuracy measurement of the attenuation
coefficient in discrimination of malignancy and stroma showed
an AUC of 0.62. For a threshold value of 4.6 mm−1, the test has
Table 3 Overview of the mean attenuation (mm−1) coefficient per histological category per patient. Only patients with malignant OCT data were
included in the analysis. (standard deviation) [number of b-scan excluded/total number of b-scans (percentage of b-scans excluded)].
AC stroma (mm−1) AC inflammation (mm−1) AC Gleason 3 (mm−1) AC Gleason 4 (mm−1)
1 4.9 (1.0) 4.5 (0.8) — 6.5 (1.1)
[30/95 (32%)] [26/80 (33%)] [1/32 (3%)]
2 4.5 (0.8) — 4.8 (0.8) —
[256/672 (38%)] [35/80 (44%)]
3 5.00 (0.9) 4.8 (0.6) — 4.9 (0.7)
[307/672 (46%)] [13/32 (41%)] [184/1136 (16%)]
4 — — — —
5 — — — —
6 4.6 (1.5) — — 6.1 (1.4)
[57/128 (45%)] [2/48 (4%)]
7 4.6 (0.9) — — 4.6 (0.6)
[78/208 (38%)] [89/384 (23%)]
8 4.5 (0.9) 4.5 (1.4) — 5.6 (1.0)
[256/672 (38%)] [8/16 (50%)] [2/16 (13%)]
9 — — — —
10 4.8 (0.8) — — 4.6 (0.6)
[98/400 (25%)] [15/48 (31%)]
11 4.8 (1.1) — — 5.2 (0.8)
[55/96 (57%)] [37/128 (29%)]
12 — — — —
13 4.3 (0.8) — 6.1 (0.7) 6.1 (0.4)
[93/144 (65%)] [1/48 (2%)] [4/16 (25%)]
14 — — — —
15 — — — —
16 — — — —
17 4.6 (0.7) — — 4.9 (0.9)
[182/640 (28%)][48/112 (43%)]
18 6.4 (2.1) — — 5.4 (1.0)
[688/2240) (31%)][61/128 (48%)]
19 — — — —
20 4.4 (0.8) — — 4.3 (0.8)
[25/48 (52%)][39/80 (49%)]
Mean 4.4 (0.9) 4.7 (1.0) 5.5 (1.0) 5.1 (0.9)
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a sensitivity of 68% and a specificity of 49% (Fig. 8). Separate
categories were analyzed with a Kruskal Wallis test (Fig. 9),
which showed a significant difference in median attenuation
coefficient between stroma, inflammation, Gleason 3, and
Gleason 4 (4.6, 4.1, 5.9, and 5.0 mm−1, respectively) (p<0.05).
Since attenuation coefficient strongly differed per patient, we
also decided to perform a paired samples Wilcoxon signed-
rank test. The dot-and-line diagram is shown in Fig. 10. The
paired samples T-test does not show a significant difference
in optical attenuation coefficient between benign and malignant
tissues in the prostate per individual patient p ¼ 0.17.
4 Discussion
This study demonstrates that needle-based OCT can identify
unique tissue patterns in benign and malignant prostatic tissue
and is even able to distinguish benign tissue from malignant
prostate (p < 0.05). Visually, all types of prostatic tissue
were identifiable on OCT, although malignancy, stroma, and
inflammation present as similar patterns and therefore it was
more challenging to differentiate between those categories.
Additional computed OCT analysis by means of the attenuation
coefficient did contribute to discrimination of benign from
malignant tissue in the prostate. However, when analyzed on
Fig. 7 Per patient analysis of optical attenuation coefficients of histological categories per patient, means
with 1 SD error bars.
Fig. 8 (a) Mean attenuation coefficients for stroma and malignancy with 1 SD error bars. (b) ROC
analysis.
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a per patient basis, there was no significant difference in optical
attenuation coefficient. The unique aspect of this study is the one
to one correlation of OCTand histopathology in prostate cancer.
In previous work, the correlation of histopathology and OCT
scans was a serious drawback.10,14 For this reason, a customized
tool for OCT measurement and prostate slicing was developed.
The feasibility of precise correlation of histopathology and OCT
of the device was described in earlier work.25 Using this method,
we performed a single blind qualitative and quantitative accu-
racy study of OCT in a larger cohort of 20 patients ex vivo.
4.1 Limitations on Data Matching
The correlation of 3-D OCT scans and 2-D histopathology was
based on two assumptions. First, OCT probe rotation in the
prostate tissue was approximated by corresponding structures
seen in OCT and histology. The estimated rotational inaccuracy
is 10 deg, which we consider a small inaccuracy. Second, when
both sides of the trajectory contained identical histological struc-
tures, it was assumed that all tissue surrounding the OCT probe
was from the same histological category. Although this seems
plausible, histopathology showed a large heterogeneity in pros-
tatic tissue; therefore, it might be possible that some areas
contain tissue from another category. In order to minimize meas-
urement errors, we identified five B-scans on both sides of the
ROIs as the margin of error and excluded them from data
analysis.
Because the OCT-probe only samples part of the tissue, we
missed the tumor in eight patients. For this reason, we did not
include this OCT data in the visual assessment and we were not
able to analyze the attenuation coefficient on malignancy in
these patients.
4.2 Limitations in Visual Assessment
For visual assessment, the observers were affiliated with OCT
but were not formally trained for detection of prostate cancer.
Therefore, it is plausible that their assessment scores can be
improved by OCT assessment training. This training could con-
sist of an explanation of the unique tissue characteristics
followed by an extended test of prostatic B-scans. This method
has been successfully executed before in other imaging studies,
e.g., using MRI to visualize prostate cancer, training signifi-
cantly increased diagnostic accuracy.27,28
4.3 Limitations in Quantitative Assessment Using
the Optical Attenuation Coefficient
It was remarkable that the optical attenuation coefficient for one
category (e.g., Gleason 4) could differ within a patient with μOCT
values ranging 1 to 2 mm−1. This intrapatient variation might
be because prostate tissue is heterogonous and is therefore
challenging for the pathologist to delineate an area as benign
or malignant. Moreover, the pathologist analyzes the whole
mount prostatic histology slide using a 40× microscope and
delineates this using software on a digital lower resolution
image of the same slide, a process prone to errors. We partially
corrected for this by removing 5 B scans from each side of each
ROI as described earlier. Yet, it is also known from histological
studies that healthy prostate tissue differs between patients and
therefore tumor tissue might differ between patients as well.29
Furthermore, a fair amount of fits (∼30%) was excluded
from the analysis because the calculated fit did not exactly
match the measured data. Most likely, these specific regions of
the prostate are too heterogeneous for a correct fit, e.g., cysts, but
they might still have a clinical significance. Technology such
as automated texture analysis and pattern recognition could con-
tribute to solve this problem and could increase the performance
of OCT for prostate cancer detection.30 Furthermore, when
more data are available, convolutional neural networks could
be trained to perform the analyses on the OCT data, as it now
starting in conventional histopathology.31
4.4 Perspective to Other Work in the Field
Ex vivo application of OCT on the human prostate was first
described in the year 2000. 2-D cross sectional OCT scans
were generated of specimens after radical prostatectomy.32 It
was claimed that OCT could distinguish malignant from benign
prostate tissue on the basis of architectural differences in the
tissue. OCT has also been described for prostatic nerve identi-
fication in order to spare them during radical prostatectomy
experiments.33,34 Dangle et al.35 evaluated surgical margins,
seminal vesicle invasion, and capsular invasion with OCT
ex vivo in prostates after radical prostatectomy. They found that
OCT overestimated the amount of margin involvement, but the
Fig. 9 Bar graph median attenuation coefficients for Gleason 3,
Gleason 4, stroma, and inflammation with 95% confidence intervals
for medians.
Fig. 10 Dot and line diagram of optical attenuation coefficient ana-
lyzed per patient. A Wilcoxon signed-rank test did not show a signifi-
cant difference between optical attenuation coefficients per patient
p ¼ 0.17.
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NPV was high. For surgical margins on OCT sensitivity,
specificity, PPV, and NPV was 70%, 84%, 33%, and 96%,
respectively. Recently, a study by Lopater et al.36 described the
initial application of full-field OCT for the detection of prostate
cancer in prostate biopsies. This ex vivo OCT imaging method
approaches the resolution of traditional histological slides with
a resolution of about 1 μm. The images were scored solely by
architectural structures and solely in the 2-D setting, sensitivity,
specificity, PPV, and NPV values were 63%, 74%, 55.5%, and
80% respectively. In our study, sensitivity (79% and 88%) and
specificity (88% and 81%) for malignancy detection were higher
than in these previous studies. PPVs (66% and 57%) and NPVs
(94% and 96%) were higher or comparable to these previous
studies. Although PPVs were higher than previous studies,
they were still considerably lower than the NPVs. This indicates
that OCT, as it is investigated here, can be a good test to exclude
disease in the prostate. The advantage of the St. Jude C7-XRtm
Intravascular Imaging System is that it is commercially available
and applicable in a sterile environment. Consequently, the appli-
cation of this OCT system in the outpatient clinic or even in a
surgery setting is relatively easy. The small probe diameter even
allows for in vivo insertion in the prostate. Images are acquired
in 3-D, which increases the amount of information substantially
when compared to 2-D histopathology. Needle-based OCT lacks
the spatial resolution to function as a stand-alone diagnostic
modality in prostate cancer. However, it can make the process
of conventional histopathology faster and possibly more accu-
rate. Since OCT results are quantifiable, it can reduce interrater
variability, which is high for conventional histopathology.37
5 Conclusion
This study validates one to one correlation of histopathology
and OCT using the uniquely designed prostate slicing device
in a cohort of 20 patients. Correlation showed that most histo-
logical tissues have a unique pattern and therefore could be vis-
ually identified on OCT, such as cysts, lines, view in depth, or
signal intensity. The abilities of OCT for prostate cancer
identification were explored and qualitative visual analysis con-
firmed the hypothesized high cell density of malignant tissue.
In addition, the optical attenuation coefficient contributes to
the differentiation between stroma and malignancy, although
a per-patient analysis did not show a significant difference.
These findings may serve as a basis for an in vivo study com-
bining OCT and prostate biopsy histopathology; allowing com-
parison of both tests and exploring the clinical potential of OCT
in digital pathology of the prostate.
Appendix: Fitting the Optical Attenuation
Coefficient
Quantification of the optical attenuation coefficient was per-
formed using custom-written code (Matlab 7.11.0 R2010b,
The Mathworks Inc., Natick, Massachusetts). Methods were
derived from our previous work.14,16,26 First, OCT amplitude
data were loaded into the software. Isolation of tissue-related
data from the original data set was achieved by a succession
of image processing steps applied to all B-Scans. First, low
SNR regions were excluded by applying a pixel value threshold
on the amplitude data. Next, to remove the catheter from the
B-Scans, an algorithm utilizing region connectivity as well as
a priori knowledge about the catheter-tissue geometry was
implemented. Following this, a 5 × 5 Gaussian low pass filter
was applied to the catheter-free images; this step served to
improve performance of the ensuing edge detection using the
Sobel method. The detected tissue edge was then smoothed fur-
ther by carrying out local regression using weighted linear least-
squares (assigning lower weight to outliers and zero weight to
data outside six mean absolute deviations) and a second-degree
polynomial model. OCT amplitude data of the prostate tissue
were isolated from the original B-Scan by selecting all data
below this smoothed edge. Finally, these data were straightened
and then divided into FRs with the following dimensions:
31 × 6 × 226 pixels in the fast axis, slow axis, and depth
(located 20 pixels below the tissue edge), respectively. These
individual FRs were then laterally averaged, yielding a single
average A-line for each FR. Subsequently, an FR-specific
attenuation coefficient (μOCT) was determined by nonlinear
least squares fitting the following equation to this average
A-line: AðzÞ ¼ tðzÞ · hðzÞ · A · exp½−μOCTðz − z0Þ þ noise.
AðzÞ is the averaged OCT amplitude in depth, z is the position
in depth, z0 is the position of the tissue boundary, A and
μOCT are free running parameters (amplitude and attenuation
coefficient, respectively). The fit always starts 20 pixels
below the tissue surface to ensure the absence of tissue edge
reflection. The noise is defined as the average of the last 100
pixels of the data. The system dependent parameter tðzÞ





q , where zf is the position of the focus in depth,
ZR0 is the Rayleigh length, and n is the refractive index of
the medium. The sensitivity roll-off hðzÞ is defined as:
hðzÞ ¼ sinc ðπ
2
· zzmaxÞ · exp½− π
2·s2
16·ln ð2Þ · ð zzmaxÞ2. Here, zmax is the
maximal imaging depth of the OCT system and s is the ratio
between the spectral resolution to the sampling interval. The
contribution of the confocal point spread function and the sen-
sitivity roll-off were determined by fitting the equation for AðzÞ
to the OCT amplitude of a sample with a low concentration of
Intralipid (0.003%) using four different catheters, for which
negligible scattering is assumed, and ZR0 and s were the free
running parameters.38,39 The median values for ZR0 and s are
0.73 mm and 1.4, respectively, which corresponds to reported
values.40,41 After fitting, all fits were judged by an experienced
observer and nonmatching fits (e.g., because of a cyst in the
data) were excluded from the analysis. In this way, only accurate
representations of the optical attenuation coefficient were
included in the analysis. Finally, all obtained attenuation coef-
ficient values were multiplied by 1.4 (refractive index for tissue)
yielding values per mm.42
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